IRVINE, Calif., July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21. After a successful first year, JUVÉDERM® Day is back with limited time offers, savings, and exclusive deals through Allē, the Allergan Aesthetics loyalty rewards program.
"JUVÉDERM® Day 2023 logged the most treatments in a single day for the brand, and our goal is to surpass that this year. During this year's event, we are providing even more exclusive offers to drive consumers into practices," said Jasson Gilmore, Senior Vice President U.S. Aesthetics. "Now is the perfect time for consumers to speak with their aesthetic specialist about treatment with products in the JUVÉDERM® Collection of Fillers to achieve smooth, natural-looking, and long-lasting results."
More than 18 million consumers are interested in receiving treatment with dermal filler, and JUVÉDERM® offers a robust collection of products specifically designed to address consumers' top aesthetic concerns. JUVÉDERM® remains the number one chosen hyaluronic acid (HA) dermal filler collection on the market and is trusted by providers globally1.
Consumers eager to try treatment and participate in JUVÉDERM® Day are encouraged to join Allē at alle.com/registration to receive exclusive offers, including:
"As we continue to see consumer trends shift towards a more natural-looking aesthetic, my patients are coming to me specifically looking for subtle treatment outcomes, and I trust the JUVÉDERM® Collection of Fillers to help me deliver the results they desire," said Dr. Deborah Sherman, Board-certified ophthalmologist, Fellowship-trained Oculofacial Plastic Surgeon, and founder of Sherman Aesthetic Center in Nashville, Tenn. "The JUVÉDERM® Day celebration provides a great opportunity to spark new conversations around my patients' aesthetic goals."
JUVÉDERM® Day is recognized by National Day Archives as an official holiday on the National Day Registry™, JUVÉDERM® Day will be held annually on the third Wednesday of August. For more information on the JUVÉDERM® Collection of Fillers, visit Juvederm.com and follow @JUVEDERM on Instagram and TikTok.
In serving more than seven million Members across ~30,000 practices to date, part of Allē's mission is to help educate consumers about aesthetic treatments, and to simplify office operations for practices. From its inception, Allē has disrupted the aesthetics industry by offering the most robust rewards program. Allē is the first and only loyalty program in the aesthetics market to also offer consumers the ability to earn points on over 50 non-Allergan Aesthetics treatments and brands. By providing Members with information, tools, and incentives, and now with flexible ways to pay though Allē Payment Plans, Allē empowers consumers along their treatment journey, making the next product purchase or treatment closer within reach.
*NO PURCHASE NECESSARY TO ENTER TO WIN. Open to Allē Members in 50 U.S./D.C.; 18+ (19+ in AL, NE, 21+ in MS) Void where prohibited. Registration starts 08/21/2024. See full Official Rules for all details and how to enter without purchase at https://alle.com/lp/juvdaysweeps-official-rules.
†Gift cards can be used exclusively towards treatment with any product in the JUVÉDERM® Collection of Fillers. SKINVIVE by JUVÉDERM® is excluded from all promotions.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
JUVÉDERM® Injectable Gel Fillers Important Information
APPROVED USES
JUVÉDERM® VOLUX® XC injectable gel is for deep injection to improve moderate to severe loss of jawline definition in adults over the age of 212.
JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 213.
JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC injectable gels are for injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds 4–6. JUVÉDERM® VOLLURE® XC injectable gel is for adults over 214.
JUVÉDERM® Ultra XC injectable gel is also for injection into the lips and perioral area for lip augmentation in adults over 215.
JUVÉDERM® VOLBELLA® XC injectable gel is for injection into the lips for lip augmentation and correction of perioral lines, and for injection into the undereye hollows to improve the appearance of undereye hollows in adults over the age of 217.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any JUVÉDERM® formulation?
Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.
What warnings should my doctor advise me about?
What precautions should my doctor advise me about?
What are possible side effects of treatment?
The most commonly reported side effects with JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported.
These side effects are consistent with other facial injection procedures and most will resolve within 30 days. Your doctor may choose to treat side effects persisting longer with antibiotics, steroids, or hyaluronidase (an enzyme that breaks down hyaluronic acid).
As with all skin injection procedures, there is a risk of infection.
To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372. Please also visit Juvederm.com or talk to your doctor for more information.
Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.
References:
© 2024 AbbVie. All rights reserved. JUVÉDERM and its designs are trademarks of Allergan Holdings France SAS, and AbbVie company, or its affiliates. All other trademarks are property of their respective owners.
Last Trade: | US$175.72 |
Daily Change: | -7.21 -3.94 |
Daily Volume: | 5,828,930 |
Market Cap: | US$311.020B |
December 11, 2024 December 09, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB